HOOK · HOOKIPA Pharma Inc.
$1.15
At close · Jun 2
Going-concern doubt
— flagged May 15, 2025
Substantial doubt about the company's ability to continue as a going concern.
“As of the filing date of this Quarterly Report on Form 10-Q, the Company's expectation to generate negative operating cash flows in the future and the need for additional funding to support its planned operations raise substantial doubt regarding the Company's ability to continue as a going concern for a period of one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed May 15, 2025
Market Cap
$14.02M
Shares
12.19M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Joern Aldag | Chief Executive Officer | $1,130,427 |
| Christine Baker | Former Chief Operating Officer | $813,399 |
| Reinhard Kandera | Chief Financial Officer | $725,475 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Joern Aldag | Chief Executive Officer | $1,250,408 |
| Christine Baker | Chief Operating Officer | $873,624 |
| Reinhard Kandera | Chief Financial Officer | $715,161 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Joern Aldag | Chief Executive Officer | $2,605,450 |
| Reinhard Kandera | Chief Financial Officer | $1,175,312 |
| Christine Baker | Chief Operating Officer | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Joern Aldag | Chief Executive Officer | $6,367,981 |
| Reinhard Kandera | Chief Financial Officer | $1,348,479 |
| Igor Matushansky | Chief Medical Officer | $1,142,714 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Igor Matushansky | Chief Medical Officer | $805,904 |
| Joern Aldag | Chief Executive Officer | $547,592 |
| Reinhard Kandera | Chief Financial Officer | $456,633 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Julie O'Neill | non-executive chair of the Board | Appointed | 2024-08-30 |
| Timothy Reilly | director | Resigned | 2024-08-30 |
| Jan van de Winkel | director | Resigned | 2024-08-30 |
| Malte Peters, M.D. | Chief Executive Officer | Appointed | 2024-07-26 |
| Reinhard Kandera | director | Resigned | 2024-07-26 |
| Joern Aldag | director | Resigned | 2024-07-26 |
| Roman Necina | Chief Operations Officer | Appointed | 2023-12-01 |
| Christine Baker | Chief Operating Officer | Resigned | 2023-10-20 |
| Terry Coelho | Chair of the Audit Committee | Appointed | 2023-04-13 |
| Michael A. Kelly | member of the Board | Resigned | 2023-04-13 |
| Terry Coelho | director of the Board | Appointed | 2023-03-13 |
| Malte Peters, M.D. | director | Appointed | 2022-12-15 |
| Roman Necina | Chief Development Officer (CDO) | Appointed | 2022-06-22 |
| Katia Schlienger | Executive Vice President, Clinical Development | Appointed | 2022-06-22 |
| Igor Matushansky | Chief Medical Officer and Global Head of Research and Development | Resigned | 2022-06-22 |
| Christine D. Baker | Chief Operating Officer | Appointed | 2022-05-02 |
| Timothy Reilly | director of the Board | Appointed | 2022-04-20 |
Key facts
CIK
1760542
CUSIP
43906K209